-
公开(公告)号：EP0663912A4
公开(公告)日：1995-02-17
申请号：EP93923826
申请日：1993-10-08
Applicant: ABBOTT LAB
Inventor： ABREO MELWYN A , GUNN DAVID E , LIN NAN-HORNG , ELLIOTT RICHARD L , GARVEY DAVID S , LEBOLD SUZANNE A , WASICAK JAMES T
IPC: A61K31/427 , A61K31/439 , A61K31/44 , A61K31/4427 , A61K31/4439 , A61K31/444 , A61K31/4545 , A61K31/47 , A61K31/4709 , A61K31/497 , A61K31/501 , A61P25/00 , A61P25/28 , C07D401/12 , C07D403/12 , C07D411/12 , C07D417/12 , C07D471/08 , C07D487/04 , A61K31/425 , A61K31/445 , A61K31/495 , A61K31/50 , A61K31/505 , C07D453/02
CPC classification number: C07D401/12 , C07D403/12 , C07D417/12
-
2.发明专利
公开(公告)号：CA2315117C
公开(公告)日：2011-03-15
申请号：CA2315117
申请日：1998-12-18
Applicant: ABBOTT LAB
Inventor： HOLLADAY MARK W , ABREO MELWYN A , GUNN DAVID E , LIN NAN-HORNG , GARVEY DAVID S , RYTHER KEITH , LEBOLD SUZANNE A , ELLIOTT RICHARD L , HE YUN , WASICAK JAMES T , BAI HAO , DART MICHAEL J , EHRLICH PAUL P , LI YIHONG , KINCAID JOHN F , SCHKERYANTZ JEFFREY M , LYNCH JOHN K
IPC: C07D401/12 , A61K31/40 , A61K31/425 , A61K31/427 , A61K31/44 , A61K31/4427 , A61K31/4439 , A61K31/4545 , A61K31/47 , A61K31/4709 , A61K31/4725 , A61K31/497 , A61K31/50 , A61K31/501 , A61K31/505 , A61K31/506 , A61P25/00 , A61P25/22 , A61P25/28 , A61P25/30 , A61P43/00 , C07D403/12 , C07D417/12 , C07D455/02 , C07D487/04
Abstract: Novel compounds having formulas (I), (II) or (III) or pharmaceutically-acceptable salts or prodrugs thereof, which are useful for controlling synaptic transmission; to therapeutically-effective pharmaceutical compositions of these compounds; and to the use of said compositions to controlling synaptic transmission in human or veterinary patients.
-
公开(公告)号：ES2169727T3
公开(公告)日：2002-07-16
申请号：ES93923826
申请日：1993-10-08
Applicant: ABBOTT LAB
Inventor： ABREO MELWYN A , GUNN DAVID E , LIN NAN-HORNG , ELLIOTT RICHARD L , GARVEY DAVID S , LEBOLD SUZANNE A
IPC: A61K31/427 , A61K31/439 , A61K31/44 , A61K31/4427 , A61K31/4439 , A61K31/444 , A61K31/4545 , A61K31/47 , A61K31/4709 , A61K31/497 , A61K31/501 , A61P25/00 , A61P25/28 , C07D401/12 , C07D403/12 , C07D411/12 , C07D417/12 , C07D471/08 , C07D487/04 , A61K31/425 , A61K31/445 , A61K31/495 , A61K31/50 , A61K31/505 , C07D453/02
Abstract: Novel heterocyclic ether compounds of formula (I), wherein A, B and R are specifically defined, or pharmaceutically-acceptable salts or prodrugs thereof, which are selective and potent ligands at cholinergic channel receptors, useful in the treatment of cognitive, neurological and mental disorders characterized by decreased cholinergic function.
-
4.发明专利
公开(公告)号：CA2315117A1
公开(公告)日：1999-07-01
申请号：CA2315117
申请日：1998-12-18
Applicant: ABBOTT LAB
Inventor： HE YUN , LEBOLD SUZANNE A , ELLIOTT RICHARD L , BAI HAO , DART MICHAEL J , WASICAK JAMES T , KINCAID JOHN F , GARVEY DAVID S , LI YIHONG , RYTHER KEITH , HOLLADAY MARK W , EHRLICH PAUL P , ABREO MELWYN A , GUNN DAVID E , LIN NAN-HORNG , SCHKERYANTZ JEFFREY M , LYNCH JOHN K
IPC: A61K31/427 , A61K31/4427 , A61K31/4439 , A61K31/4545 , A61K31/4709 , A61K31/4725 , A61K31/497 , A61K31/501 , A61K31/506 , A61P25/00 , A61P25/22 , A61P25/28 , A61P25/30 , A61P43/00 , C07D401/12 , C07D403/12 , C07D417/12 , C07D455/02 , C07D487/04 , A61K31/40 , A61K31/425 , A61K31/44 , A61K31/47 , A61K31/50 , A61K31/505
Abstract: Novel compounds having formulas (I), (II) or (III) or pharmaceuticallyacceptable salts or prodrugs thereof, which are useful for controlling synaptic transmission; to therapeutically-effective pharmaceutical compositions of these compounds; and to the use of said compositions to controlling synaptic transmission in human or veterinary patients.
-
5.发明专利
公开(公告)号：CA2233550C
公开(公告)日：2010-06-22
申请号：CA2233550
申请日：1996-09-25
Applicant: ABBOTT LAB
Inventor： BROOKS CLINT D W , BHATIA PRAMILA , KOLASA THEODOZYJ , STEWART ANDREW O , GUNN DAVID E , CRAIG RICHARD A
IPC: C07D215/14 , C07D239/26 , A61K31/41 , A61K31/4184 , A61K31/421 , A61K31/44 , A61K31/4402 , A61K31/454 , A61K31/47 , A61K31/495 , A61K31/498 , A61K31/506 , A61P37/08 , A61P43/00 , C07D213/30 , C07D213/55 , C07D215/18 , C07D235/12 , C07D235/20 , C07D241/42 , C07D263/56 , C07D277/24 , C07D277/30 , C07D277/64 , C07D401/14 , C07D413/14 , C07D417/14
Abstract: Compounds having formula (I), wherein W is the same at each occurrence and is selected from optionally substituted quinolyl, optionally substituted benzothiazolyl, optionally substituted benzoxazolyl, optionally substituted benzimidazolyl, optionally substituted quinoxalyl, optionally substituted pyridyl, optionally substituted pyrimidyl, and optionally substituted thiazolyl; R1 and R2 are independently selected from hydrogen, alkyl, haloalkyl, alkoxy, halogen; R3 is a valence bond or is selected from hydrogen and alkyl; X is a valence bond or is selected from alkylene, alkenylen, and alkynylene; and Z is selected from (a) COM, (b) CH=N-O-A-COM, (c) CH2-O-N=A-COM wherein A is selected from alkylene and cycloalkylene, and M is selected from (a) a pharmaceutically acceptable metabolically cleavable group, (b) -OR6, (c) -NR7R8, (d) -NR6SO2R9, (e) -NH-Tetrazolyl, and (f) glycinyl inhibit leukotriene biosynthesis and are useful in the treatment of allergic and inflammatory disease states. Also disclosed are leukotriene biosynthesis inhibiting compositions and a method of inhibiting leukotriene biosynthesis.
-
Patent Agency Ranking
公开(公告)号：AT262519T
公开(公告)日：2004-04-15
申请号：AT98964167
申请日：1998-12-18
Applicant: ABBOTT LAB
Inventor： HOLLADAY MARK W , ABREO MELWYN A , GUNN DAVID E , LIN NAN-HORNG , GARVEY DAVID S , RYTHER KEITH , LEBOLD SUZANNE A , ELLIOTT RICHARD L , HE YUN , WASIAK JAMES T , BAI HAO , DART MICHAEL J , EHRLICH PAUL P , LI YIHONG , KINCAID JOHN F , SCHKERYANTZ JEFFREY M , LYNCH JOHN K
IPC: A61K31/427 , A61K31/4427 , A61K31/4439 , A61K31/4545 , A61K31/4709 , A61K31/4725 , A61K31/497 , A61K31/501 , A61K31/506 , A61P25/00 , A61P25/22 , A61P25/28 , A61P25/30 , A61P43/00 , C07D401/12 , C07D403/12 , C07D417/12 , C07D455/02 , C07D487/04 , A61K31/40 , A61K31/425 , A61K31/44
-
公开(公告)号：PT862557E
公开(公告)日：2003-04-30
申请号：PT96932335
申请日：1996-09-25
Applicant: ABBOTT LAB
Inventor： BHATIA PRAMILA , CRAIG RICHARD A , BROOKS CLINT D W , KOLASA THEODOZYJ , STEWART ANDREW O , GUNN DAVID E
IPC: C07D239/26 , A61K31/4184 , A61K31/421 , A61K31/4402 , A61K31/454 , A61K31/47 , A61K31/498 , A61K31/506 , A61P37/08 , A61P43/00 , C07D213/30 , C07D215/14 , C07D215/18 , C07D235/12 , C07D241/42 , C07D263/56 , C07D277/24 , C07D277/64 , C07D417/14 , A61K31/395
Abstract: Compounds having the formula: wherein W is the same at each occurrence and is selected from optionally substituted quinolyl, optionally substituted benzothiazolyl, optionally substituted benzoxazolyl, optionally substituted benzimidazolyl, optionally substituted quinoxalyl, optionally substituted pyridyl, optionally substituted pyrimidyl, and optionally substituted thiazolyl; R1 and R2 are independently selected from hydrogen, alkyl, halolalkyl, alkoxy, halogen; R3 is a valence bond or is selected from hydrogen and alkyl; X is a valence bond or is selected from alkylene, alkenylen, and alkynylene; and Z is selected from (a) COM, (b) CH=N-O-A-COM, (c) CH2-O-N=A-COM wherein A is selected from alkylene and cycloalkylene, and M is selected from (a) a pharmaceutically acceptable metabolically cleavable group, (b) -OR6, (c) -NR7R8, (d)-NR6SO2R9, (e)-NH-Tetrazolyl, and (f) glycinyl inhibit leukotriene biosynthesis and are useful in the treatment of allergic and inflammatory disease states. Also disclosed are leukotriene biosynthesis inhibiting compositions and a method of inhibiting leukotriene biosynthesis.
-
公开(公告)号：ES2188788T3
公开(公告)日：2003-07-01
申请号：ES96932335
申请日：1996-09-25
Applicant: ABBOTT LAB
Inventor： BROOKS CLINT D W , BHATIA PRAMILA , KOLASA THEODOZYJ , STEWART ANDREW O , GUNN DAVID E , CRAIG RICHARD A
IPC: C07D239/26 , A61K31/4184 , A61K31/421 , A61K31/4402 , A61K31/454 , A61K31/47 , A61K31/498 , A61K31/506 , A61P37/08 , A61P43/00 , C07D213/30 , C07D215/14 , C07D215/18 , C07D235/12 , C07D241/42 , C07D263/56 , C07D277/24 , C07D277/64 , C07D417/14 , A61K31/395
Abstract: Compounds having the formula: wherein W is the same at each occurrence and is selected from optionally substituted quinolyl, optionally substituted benzothiazolyl, optionally substituted benzoxazolyl, optionally substituted benzimidazolyl, optionally substituted quinoxalyl, optionally substituted pyridyl, optionally substituted pyrimidyl, and optionally substituted thiazolyl; R1 and R2 are independently selected from hydrogen, alkyl, halolalkyl, alkoxy, halogen; R3 is a valence bond or is selected from hydrogen and alkyl; X is a valence bond or is selected from alkylene, alkenylen, and alkynylene; and Z is selected from (a) COM, (b) CH=N-O-A-COM, (c) CH2-O-N=A-COM wherein A is selected from alkylene and cycloalkylene, and M is selected from (a) a pharmaceutically acceptable metabolically cleavable group, (b) -OR6, (c) -NR7R8, (d)-NR6SO2R9, (e)-NH-Tetrazolyl, and (f) glycinyl inhibit leukotriene biosynthesis and are useful in the treatment of allergic and inflammatory disease states. Also disclosed are leukotriene biosynthesis inhibiting compositions and a method of inhibiting leukotriene biosynthesis.
-
公开(公告)号：DK0862557T3
公开(公告)日：2003-03-24
申请号：DK96932335
申请日：1996-09-25
Applicant: ABBOTT LAB
Inventor： BROOKS CLINT D W , BHATIA PRAMILA , KOLASA THEODOZYJ , STEWART ANDREW O , GUNN DAVID E , CRAIG RICHARD A
IPC: C07D239/26 , A61K31/4184 , A61K31/421 , A61K31/4402 , A61K31/454 , A61K31/47 , A61K31/498 , A61K31/506 , A61P37/08 , A61P43/00 , C07D213/30 , C07D215/14 , C07D215/18 , C07D235/12 , C07D241/42 , C07D263/56 , C07D277/24 , C07D277/64 , C07D417/14 , A61K31/395
Abstract: Compounds having the formula: wherein W is the same at each occurrence and is selected from optionally substituted quinolyl, optionally substituted benzothiazolyl, optionally substituted benzoxazolyl, optionally substituted benzimidazolyl, optionally substituted quinoxalyl, optionally substituted pyridyl, optionally substituted pyrimidyl, and optionally substituted thiazolyl; R1 and R2 are independently selected from hydrogen, alkyl, halolalkyl, alkoxy, halogen; R3 is a valence bond or is selected from hydrogen and alkyl; X is a valence bond or is selected from alkylene, alkenylen, and alkynylene; and Z is selected from (a) COM, (b) CH=N-O-A-COM, (c) CH2-O-N=A-COM wherein A is selected from alkylene and cycloalkylene, and M is selected from (a) a pharmaceutically acceptable metabolically cleavable group, (b) -OR6, (c) -NR7R8, (d)-NR6SO2R9, (e)-NH-Tetrazolyl, and (f) glycinyl inhibit leukotriene biosynthesis and are useful in the treatment of allergic and inflammatory disease states. Also disclosed are leukotriene biosynthesis inhibiting compositions and a method of inhibiting leukotriene biosynthesis.
-
10.发明专利
公开(公告)号：DE69625080D1
公开(公告)日：2003-01-09
申请号：DE69625080
申请日：1996-09-25
Applicant: ABBOTT LAB
Inventor： BROOKS CLINT D W , BHATIA PRAMILA , KOLASA THEODOZYJ , STEWART ANDREW O , GUNN DAVID E , CRAIG RICHARD A
IPC: C07D239/26 , A61K31/4184 , A61K31/421 , A61K31/4402 , A61K31/454 , A61K31/47 , A61K31/498 , A61K31/506 , A61P37/08 , A61P43/00 , C07D213/30 , C07D215/14 , C07D215/18 , C07D235/12 , C07D241/42 , C07D263/56 , C07D277/24 , C07D277/64 , C07D417/14 , A61K31/395
Abstract: Compounds having the formula: wherein W is the same at each occurrence and is selected from optionally substituted quinolyl, optionally substituted benzothiazolyl, optionally substituted benzoxazolyl, optionally substituted benzimidazolyl, optionally substituted quinoxalyl, optionally substituted pyridyl, optionally substituted pyrimidyl, and optionally substituted thiazolyl; R1 and R2 are independently selected from hydrogen, alkyl, halolalkyl, alkoxy, halogen; R3 is a valence bond or is selected from hydrogen and alkyl; X is a valence bond or is selected from alkylene, alkenylen, and alkynylene; and Z is selected from (a) COM, (b) CH=N-O-A-COM, (c) CH2-O-N=A-COM wherein A is selected from alkylene and cycloalkylene, and M is selected from (a) a pharmaceutically acceptable metabolically cleavable group, (b) -OR6, (c) -NR7R8, (d)-NR6SO2R9, (e)-NH-Tetrazolyl, and (f) glycinyl inhibit leukotriene biosynthesis and are useful in the treatment of allergic and inflammatory disease states. Also disclosed are leukotriene biosynthesis inhibiting compositions and a method of inhibiting leukotriene biosynthesis.
-
-
-
-
-
-
-
-
-
Search Results
28
records
(took 0.02 seconds)
